Home > Press > Microfluidics International Corporation Announces Second Quarter 2008 Results
 |
Abstract:
Microfluidics International Corporation, (OTCBB: MFIC), an industry-leader in high-shear liquid processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries, today reported financial results for the second quarter of 2008.
Microfluidics International Corporation Announces Second Quarter 2008 Results
NEWTON, MA | Posted on August 12th, 2008Second Quarter Highlights
-- Recorded highest second quarter revenue in the Company's history of $4.4 million
-- Addressed working capital needs with signing of $2.5 million multi-year revolving credit line
-- Completed executive leadership team with the appointment of a new Executive Vice President and Chief Financial Officer, Chief Technology Officer, and Vice President of Customer Success
-- Finalized three year strategic plan focused on double-digit top line organic global growth
-- Changed name to Microfluidics International Corporation to enhance global branding
For the quarter ended June 30, 2008 the Company reported revenues of $4.4 million, an increase of 23.0% from $3.6 million in the second quarter of 2007 and a negative EBITDA of $(754,000) or $(0.07) per share for the second quarter of 2008 as compared to a negative EBITDA of $(82,000) or $(0.01) per share for the same period in 2007.
Net loss for the second quarter 2008 was $(790,000) or $(0.08) per share as compared to a net loss of $(107,000) or $(0.01) per share for the second quarter ended June 30, 2007.
The Company's order backlog as of June 30, 2008 was $2.7 million compared to backlog of $2.9 million as of June 30, 2007. The decrease in backlog was primarily a result of North American order timing delays of large production machines.
"Our focus on revenue growth, properly building the Company's infrastructure, and rounding out our leadership team remained our top priority this quarter," said Michael C. Ferrara, President and Chief Executive Officer. "We are not pleased with the EBITDA results for the quarter. However, we are in the process of addressing this issue on several fronts and we will align the operating expenses as required on our path to profitability. Strong performance with our large pharmaceutical customers, combined with our initial success in globally expanding our distribution resources are our plans to deliver top line results that will support our growth initiatives."
Brian E. LeClair, Executive Vice President and Chief Financial Officer, added, "Our EBITDA for the second quarter was below our expectations. The loss in the quarter was driven by a decline in our gross margins and an increase in operating expenses. The decline in margins was associated with sales of our lab units which were introduced in the previous quarter at lower margins and higher sales of the custom production machines. We have put corrective plans in place to address the margin decline that should bring our margins back in line with historical levels. Results were also adversely affected by an increase in operating expenses associated with building our leadership team and making investments in our future growth."
####
About Microfluidics International Corporation
MICROFLUIDICS INTERNATIONAL CORPORATION
Condensed Consolidated Statements of Operations
(Unaudited - in thousands, except share and per share amounts)
For The Three Months Ended For The Six Months Ended
June 30, June 30,
-------------------------- -------------------------
2008 2007 2008 2007
------------- ------------ ------------ ------------
Revenues $ 4,374 $ 3,557 $ 7,896 $ 6,358
Cost of goods
sold 2,225 1,453 3,834 2,646
------------- ------------ ------------ ------------
Gross profit 2,149 2,104 4,062 3,712
------------- ------------ ------------ ------------
Operating
expenses:
Research and
development 572 438 1,062 974
Selling 1,196 984 2,128 1,808
General and
administrative 1,175 805 2,118 1,483
------------- ------------ ------------ ------------
Total operating
expenses 2,943 2,227 5,308 4,265
------------- ------------ ------------ ------------
Loss from
operations (794) (123) (1,246) (553)
Interest expense (6) (1) (10) (9)
Interest income 10 17 21 38
------------- ------------ ------------ ------------
Net loss $ (790) $ (107) $ (1,235) $ (524)
============= ============ ============ ============
Net loss per
common share:
Basic $ (0.08) $ (0.01) $ (0.12) $ (0.05)
Diluted $ (0.08) $ (0.01) $ (0.12) $ (0.05)
Weighted average
number of common
and common
equivalent
shares
outstanding:
Basic 10,267,981 10,180,413 10,267,981 10,151,749
Diluted 10,267,981 10,180,413 10,267,981 10,151,749
-0-
MICROFLUIDICS INTERNATIONAL CORPORATION
Condensed Consolidated Balance Sheets
(Unaudited - in thousands, except share and per share amounts)
June 30, December 31,
2008 2007
------------ ------------
ASSETS
Current assets:
Cash and cash equivalents $ 1,162 $ 756
Accounts receivable, net of allowance of
$41 both at June 30, 2008 and December
31, 2007, respectively 2,250 2,582
Inventories 2,638 2,353
Prepaid and other current assets 688 281
------------ ------------
Total current assets 6,738 5,972
Property and equipment, net 849 325
Patents and licenses, net 58 60
------------ ------------
Total assets $ 7,645 $ 6,357
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Revolving credit line $ 1,012 $ 262
Current maturities of long-term debt and
obligations under capital lease - 65
Accounts payable 1,449 129
Accrued expenses 1,069 725
Customer advances 464 409
------------ ------------
Total current liabilities 3,994 1,590
------------ ------------
Total liabilities 3,994 1,590
------------ ------------
Stockholders' equity:
Common stock; $.01 par value; 20,000,000
shares authorized; 10,528,427 and
10,517,178 shares issued; 10,267,981 and
10,256,732 shares outstanding as of June
30, 2008 and December 31, 2007,
respectively. 105 105
Additional paid-in capital 17,497 17,378
Accumulated deficit (13,263) (12,028)
Treasury stock, 260,446 shares, at cost,
as of June 30, 2008 and December 31, 2007 (688) (688)
------------ ------------
Total stockholders' equity 3,651 4,767
------------ ------------
Total liabilities and stockholders'
equity $ 7,645 $ 6,357
============ ============
-0-
MICROFLUIDICS INTERNATIONAL CORPORATION
U.S. GAAP TO Non-GAAP Measure Reconciliations and
Earnings Before Interest, Taxes, Depreciation and Amortization
(EBITDA)
(In thousands, except share and per share amounts)
Quarter Ended Six Months Ended
June 30, June 30,
------------------------- -------------------------
2008 2007 2008 2007
------------------------- -------------------------
Net loss $ (790) $ (107) $ (1,235) $ (524)
Net interest
income (4) (16) (10) (29)
Depreciation and
amortization 40 41 81 83
------------------------- -------------------------
EBITDA (Non-GAAP
Measure) $ (754) $ (82) $ (1,164) $ (470)
------------------------- -------------------------
Weighted average
number of common
and common
equivalent shares
outstanding:
Basic: 10,267,981 10,180,413 10,267,981 10,151,749
Diluted: 10,267,981 10,180,413 10,267,981 10,151,749
EBITDA per common
share (Non-GAAP
Measure):
Basic: $ (0.07) $ (0.01) $ (0.11) $ (0.05)
Diluted: $ (0.07) $ (0.01) $ (0.11) $ (0.05)
Live Webcast
Microfluidics International Corporation will host a webcast at 8:30 a.m. ET today to discuss the quarterly results. To access the webcast, go to the Company's web site, www.mficcorp.com, and click on the webcast icon. If you do not have access to the Internet and wish to listen to the call, dial 888-679-8037 (international callers dial 617-213-4849). The participant passcode for this event is 84046982. An audio replay of the call will be available from 10:30 a.m. ET on Tuesday, August 12th until 11:59 p.m. ET on Tuesday, August 19th. The replay can be accessed by dialing 888-286-8010 (international callers dial 617-801-6888) and entering conference call ID # 91204941.
Safe Harbor for Forward Looking Statements
Certain statements in this press release contain "forward-looking statements." All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including the section of this press release entitled "Outlook"; any projections of earnings, revenue or other financial items relating to the Company, any statement of the plans, strategies and objectives of management for future operations; any statements concerning proposed future growth rates in the markets we serve; any statements of belief; any characterization of and the Company's ability to control contingent liabilities; anticipated trends in the Company's businesses; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words "may," "estimate," "intend," "continue," "believe," "expect," "anticipate," and other similar words. Although the Company believes that the expectations reflected in any forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties beyond the control of the Company. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to general economic conditions, geopolitical factors, future levels of general industrial manufacturing activity, future financial performance, market acceptance of new or enhanced versions of the Company's products, the pricing of raw materials, changes in the competitive environments in which the Company's businesses operate, the outcome of pending or future litigation and governmental proceedings and approvals, estimated legal costs, increases in interest rates, the Company's ability to meet its debt obligations, and risks and uncertainties listed or disclosed in the Company's reports filed with the Securities and Exchange Commission, including, without limitation, the risks identified under the heading "Risk Factors" set forth in the Company's Annual Report filed on Form 10-K. The Company does not intend, and undertakes no obligation, to update or alter any forward-looking statements.
EBITDA and Non-GAAP Measures
In addition to the results reported in accordance with generally accepted accounting standards (GAAP) within this release, the Company may reference certain information that is considered a non-GAAP financial measure. Management believes these measures are useful and relevant to management and investors in their analysis of the Company's underlying business and operating performance. Management also uses this information for operational planning and decision-making purposes. Non-GAAP financial measures should not be considered a substitute for any GAAP measures. Additionally, non-GAAP measures as presented by the Company may not be comparable to similarly titled measures reported by other companies.
One specific non-GAAP measure used by the Company is "EBITDA", which is defined as earnings before interest, taxes, depreciation and amortization. Management utilizes the line item non-GAAP operations statement for operational planning and decision-making purposes. A reconciliation of GAAP to non-GAAP financial information discussed in this release is contained in the attached exhibits.
About Microfluidics International Corporation
Microfluidics International Corporation, through its Microfluidics Division, designs, manufactures and distributes proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries. Microfluidics International Corporation applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics International Corporation equipment customers.
For more information, please click here
Contacts:
Microfluidics International Corporation
Brian E. LeClair
617-969-5452
or
FD Ashton Partners
Michael Cummings
617-897-1532
Copyright © Business Wire 2008
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Microfluidics/Nanofluidics
Implantable device shrinks pancreatic tumors: Taming pancreatic cancer with intratumoral immunotherapy April 14th, 2023
Researchers design new inks for 3D-printable wearable bioelectronics: Potential uses include printing electronic tattoos for medical tracking applications August 19th, 2022
Oregon State University research pushes closer to new therapy for pancreatic cancer May 6th, 2022
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||